The insulin‐like growth factor IGF‐I is an important fetal and postnatal growth factor, which is also involved in tissue homeostasis via regulation of proliferation, differentiation, and cell survival. To understand the role of IGF‐I in the pathophysiology of a variety of disorders, including growth disorders, cancer, and neurodegenerative diseases, a detailed knowledge of IGF‐I signal transduction is required. This knowledge may also contribute to the development of new therapies directed at the IGF‐I receptor or other signaling molecules. In this review, we will address IGF‐I receptor signaling through the JAK/STAT pathway in IGF‐I signaling and the role of cytokine‐induced inhibitors of signaling (CIS) and suppressors of cytokine signaling (SOCS). It appears that, in addition to the canonical IGF‐I signaling pathways through extracellular‐regulated kinase (ERK) and phosphatidylinositol‐3 kinase (PI3K)‐Akt, IGF‐I also signals through the JAK/STAT pathway. Activation of this pathway may lead to induction of SOCS molecules, well‐known feedback inhibitors of the JAK/STAT pathway, which also suppress of IGF‐I‐induced JAK/STAT signaling. Furthermore, other IGF‐I‐induced signaling pathways may also be modulated by SOCS. It is conceivable that the effect of these classical inhibitors of cytokine signaling directly affect IGF‐I receptor signaling, because they are able to associate to the intracellular part of the IGF‐I receptor. These observations indicate that CIS and SOCS molecules are key to cross‐talk between IGF‐I receptor signaling and signaling through receptors belonging to the hematopoietic/cytokine receptor superfamily. Theoretically, dysregulation of CIS or SOCS may affect IGF‐I‐mediated effects on body growth, cell differentiation, proliferation, and cell survival. © 2009 International Union of Biochemistry and Molecular Biology, Inc.